Thursday, 16 April 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 16 April 2026
News

Pfizer fights back over patient fury

Posted 15 April 2026 PM

Pfizer has responded to the backlash from breast cancer patients, confirming that price is a sticking point in securing a PBS listing for Tukysa but insisted that the battle for subsidy is not over.

It comes after Breast Cancer Network Australia (BCNA) accused Pfizer of “walking away from PBS pricing negotiations” claiming pharmaceutical companies are “digging in their heels” against the Australian Government’s PBS pricing model.

To see the whole article, please login

Popular

Is this Big Pharma up for sale?
8 deaths overseas but no TGA alert
Much-loved CEO suddenly passes
Pfizer names local as Interim MD
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (1)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home